Scholars World Heart Conference @ Tokyo, Japan

-

Scholars
World Heart Summit

THEME: "Enlightening the Advancements and Exploring the New Horizons in Heart Care"

November 18-19, 2019 | Tokyo, Japan

PS: https://scholarsconferences.com/heartcongress/


Heart Congress aims to advance continuous medical education and encourage a nourishing exchange of facts and ideas about a healthy heart and ways to keep it healthy throughout the lifetime. This will be the best chance to impact the biggest convention of members from the Cardiology department. This Cardiologists Meet will see as mixture of expert Cardiologists, Cardiac Surgeons, Interventional Cardiologists, Scientists, Researchers, Professors, Nurses, Educators, Healthcare Professionals, Physicians, Surgeons, Pharmacists, Students, Research Scholars and other Drug Manufacturing Medical Devices Companies along with various entrepreneurs and exhibitors. The Organizing Committee of  Heart Congress cordially invites all the people who are interested in the up-gradation of the healthcare requirements to maintain a healthy heart. We will all aim for a better and brighter future of this conference.
Scholars Conferences is proud to present the highly anticipated “Scholars World Heart Summit” (Heart Congress 2019) to be held on November 18-19, 2019 at Tokyo, Japan. The conference program consists of world-class keynote addresses, industry-led presentations, as well as extensive networking opportunities, creating an interactive platform for high-level scientific and business discussions.
Heart Congress will provide a comprehensive update on all medical, surgical, interventional, and electrophysiological topics in cardiology and also provides the opportunity for clinicians, scientists, doctors and researchers from all over the world to gather and learn the latest advances in the field of cardiology and healthcare and to exchange scientific ideas and experiences in a distinctive environment.
The Young Researcher Awards are part of a global initiative to support early career researchers, with the intention of supporting young researchers in their quest to advance the frontiers of science across a broad range of disciplines. This Award is instituted to recognize and reward young researchers with outstanding track record, a deep commitment to find innovative solutions and potential for high quality research.
Other areas to be discussed include:
  • Advanced heart failure: Where do we stand?
  • Effects of noninvasive ventilation with bi-level positive airway pressure on exercise tolerance and dyspnea in heart failure patients
  • Criticalevaluation on proper antithrombotic treatment in different groups of patientsundergoing vascular surgery
The Heart Congress covers basic and translational cardiovascular scientists from around the globe with the common goal to discover pathways to cardiovascular therapeutics and promoting cardiovascular health. This meeting has become the “go to” meeting for intra- and interdisciplinary cross-fertilization of ideas and incorporation of new approaches from the general scientific community and plays a pivotal role in the training of junior scientists and trainees.
  • Program Enquiry:
  • heartcongress@scholarsmeetings.org 

Comments

Post a Comment

Popular posts from this blog

The Truth About Dealing With Heart Failure

-
A guide to reducing risks and living well even if you develop the condition Congestive heart failure is a serious illness. But it does not, as is sometimes thought, mean the heart stops ­altogether. It signifies that the muscle is damaged and can no longer pump enough blood to meet the body’s needs. This condition, which ­affects 1 in 5 adults—usually in the later years—can shorten life. But with proper treatment, people are living longer and better with heart failure. “We have more medications at our disposal today to improve quality of life for people with a weakened heart,” says Guy L. Mintz, M.D., director of cardiovascular health and lipidology at Sandra Atlas Bass Heart Hospital in Manhasset, N.Y. Here’s what to do. Coronary artery disease and heart attacks are major causes of heart failure, says cardiologist Tamara Horwich, M.D., medical director of UCLA’s cardiac rehabilitation program in Los Angeles. Managing your risk for problems—such as hig...
Read more

Breaking Down Barriers in the Fight Against Congenital Heart Disease

-
Academic research has long been characterized by silos and protective instincts. A new crop of fresh-thinking physician scientists are turning that model on its head, and the results are saving little hearts. More than 1 in every 110 babies is born with some form of congenital heart disease. CHDs are the most common birth defect, in fact. Clinicians have made great strides in improving care for these children, and even individuals with severe diseases may now live well into adulthood. However, not all survive and many still experience significant complications.   “As a doctor in a pediatric cardiac ICU, we know there are things we want to do better,” says Michael Gaies, M.D., a cardiac intensivist and director of quality at the Congenital Heart Center at Michigan Medicine’s C.S. Mott Children’s Hospital. “We believe we can improve care for kids recovering from heart surgery if we can better control certain parts of the post-operative journey.” The problem...
Read more

Cerebrovascular Disease: A Serious Complication After Allogeneic Hematopoietic Stem Cell Transplantation

-
A study published in the  International Journal of Hematology  found that the incidence of cerebrovascular disease (CVD) was approximately 10 times higher in patients after  allogeneic hematopoietic stem cell transplantation (HSCT) compared with the general Taiwanese population. Moreover, CVD was associated with the number of high-dose cytarabine courses given. The researchers retrospectively evaluated clinical data from adult patients who underwent HSCT at an Asian tertiary medical center between January 2003 and December 2015. The study aimed to estimate CVD incidence, identify associated host-related and transplant procedure-related risk factors, and measure clinical outcomes (overall survival [OS] and disease-free survival [DFS]). Data from 459 adult allogeneic HSCT recipients were assessed. Of this patient cohort, 4.4% (20/459) developed post-transplant CVD, 2.4% (11/459) had intracranial hemorrhage (ICH), and 2.2% (10/459) had cerebrovascular infarction. Media...
Read more